Bridgewater’s Chief Scientist Joins DeepMind as Wall Street AI Talent Flows to Tech Giants
Jasjeet Sekhon's move from systematic investing to Google's AI research arm reveals how foundational machine learning capabilities are migrating from finance to tech—and what it means for both industries.
Jasjeet Sekhon, the chief scientist who built Bridgewater Associates’ AI-driven systematic investing platform, has joined Google DeepMind as chief strategy officer, marking the latest defection in a widening talent raid from Wall Street to AI research labs. The move, announced by DeepMind CEO Demis Hassabis on 18 March, signals two strategic shifts: Google’s post-Gemini consolidation of elite AI talent around compute-intensive infrastructure, and DeepMind’s pivot toward applied commercial optimization beyond pure research.
Sekhon joined Bridgewater in 2018 and architected AIA Labs, the firm’s machine learning division focused on causal inference for systematic portfolio management. During his tenure, the firm posted its highest profit in 50 years, with the flagship Pure Alpha fund returning 34% in 2025, according to Reuters. Bridgewater managed approximately $92 billion in assets as of September 2025.
The hire reflects a broader pattern: foundational AI capabilities developed in quantitative finance are now becoming core assets for AGI-scale research. Sekhon’s expertise in causal inference, interpretable machine learning, and small-data optimization—skills honed in financial engineering—align directly with DeepMind’s expansion into drug discovery, scientific optimization, and commercial product development.
“I am excited to announce that I am joining Google DeepMind as Chief Strategy Officer, partnering directly with Demis Hassabis to lead cross-cutting strategic initiatives spanning research, commercialisation, and policy.”
— Jasjeet Sekhon, Chief Strategy Officer, Google DeepMind
DeepMind’s Commercial Pivot
The appointment comes as DeepMind accelerates its shift from pure research toward revenue-generating applications. Isomorphic Labs, DeepMind’s drug discovery subsidiary, now runs 17 active programs with plans to scale into the hundreds, per Fortune. The unit has partnered with Eli Lilly, with its first cancer drug trial expected in early 2026.
Hassabis has been explicit about the strategic urgency. In January, he told CNBC that Google “was maybe a little bit slow to commercialize” its AI advantages, while OpenAI “did very well” at rapid deployment. DeepMind has since adopted what Hassabis called “startup or entrepreneurial roots”—shipping faster, prioritizing applied outcomes over incremental research.
Sekhon’s role centers on cross-functional strategy linking research priorities to commercial timelines and regulatory positioning. His background in systematic investing—where machine learning models must generate measurable economic value under uncertainty—maps directly onto DeepMind’s challenge: translating research breakthroughs into deployable products across drug discovery, materials science, and robotics.
Wall Street’s Talent Hemorrhage
Sekhon’s departure is part of a structural Talent migration from finance to AI labs. Goldman Sachs lost 106 AI-focused staffers to rivals in the 12 months through September 2023, while Bank of America shed 55, according to data cited by Fortune. Tech companies have weaponized compensation: Meta offered signing bonuses as high as $100 million to poach AI talent in 2025.
The competitive dynamic has shifted. Quantitative finance once offered the highest-paying destination for machine learning researchers willing to apply their skills commercially. Now, AI labs combine comparable or superior compensation with longer research horizons, access to frontier compute infrastructure, and the intellectual prestige of working on AGI-scale problems.
Bridgewater’s response to Sekhon’s exit underscores the strategic value of retaining institutional AI knowledge: the firm appointed him to its board of directors following his departure, ensuring continuity in oversight of AIA Labs’ systematic investment infrastructure.
AIA Labs, co-led by Bridgewater Co-CIO Greg Jensen, develops machine learning systems for causal inference in market prediction. The platform uses interpretable AI to generate systematic trading signals across macro asset classes. Sekhon joined Bridgewater in 2018 after professorships at Harvard, UC Berkeley, and Yale, and held no direct investing responsibilities—his role centered on research architecture and methodological oversight.
The Infrastructure Arms Race
Google’s talent consolidation occurs against a backdrop of unprecedented capital deployment. Alphabet, Amazon, Meta, and Microsoft are projected to invest approximately $650 billion collectively on AI infrastructure in 2026, per Bridgewater analysis cited by Reuters. Google shares have nearly doubled over the past year, driven by advances in the Gemini model family and commercial AI product launches.
The scale of investment creates a winner-take-most dynamic: firms with the deepest pockets can afford to hire elite researchers, train larger models, and sustain longer R&D cycles before monetization. DeepMind’s hiring of Sekhon reflects this logic—acquiring proven expertise in extracting commercial value from machine learning systems under uncertainty, then applying it to higher-stakes domains like drug discovery and materials science.
What to Watch
Sekhon’s first 12 months will reveal how DeepMind balances research ambition against commercial timelines. Key indicators: whether Isomorphic Labs scales to hundreds of drug programs as planned, how quickly DeepMind ships applied AI products beyond Gemini, and whether Google can match OpenAI’s product velocity without sacrificing research quality.
For quantitative finance, the strategic question is whether Wall Street can retain top-tier AI talent as tech companies offer comparable compensation plus access to frontier compute. Bridgewater’s decision to keep Sekhon on its board suggests firms may shift from exclusive employment to advisory relationships—trading control for influence.
The broader trend: machine learning capabilities developed to optimize financial portfolios are now being repurposed to optimize drug molecules, materials properties, and scientific discovery workflows. The firms that successfully recruited quantitative researchers a decade ago are now losing them to the labs building AGI. Whether that talent migration accelerates commercial AI breakthroughs—or simply reallocates scarce expertise without proportional gains—will define the next phase of the AI race.